WT1 peptide cancer vaccine composition for mucosal administration
The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.
1. A method for inducing cellular immunity in a subject, which comprises mucosally administering to the subject a cancer vaccine composition comprising:
(i) a WT1 peptide and/or a modified WT1 peptide;
(ii) a first cellular immunity induction promoter comprising a TLR7 ligand and a helper peptide.
2. The method according to claim 1 , wherein the helper peptide is peptide-25.
3. The method according to claim 2 , wherein the WT1 peptide is Db126 peptide.
4. The method according to claim 1 , wherein the WT1 peptide is Db126 peptide.
5. The method according to claim 1 , wherein mucosally administering comprises orally administering.
6. The method according to claim 1 , wherein mucosally administering comprises sublingual administering.
7. The method according to claim 1 , wherein mucosally administering comprises nasally administering.
8. The method according to claim 1 , wherein the vaccine composition is in the form of a film preparation.
9. The method according to claim 1 , wherein the vaccine composition is in the form of a liquid formulation.
10. The method according to claim 1 , wherein the vaccine composition is in the form of an orally-disintegrating tablet.
11. The method according to claim 1 , wherein the TLR7 ligand is TLR7-II or resiquimod.
12. The method according to claim 11 , wherein the TLR7 ligand is TLR7-II.
13. The method according to claim 11 , wherein the TLR7 ligand is resiquimod.
14. The method according to claim 11 , wherein the helper peptide is peptide-25.
15. The method according to claim 14 , wherein the WT1 peptide is Db126 peptide.
16. The method according to claim 11 , wherein the WT1 peptide is Db126 peptide.
17. The method according to claim 11 , wherein mucosally administering comprises orally administering.
18. The method according to claim 11 , wherein mucosally administering comprises sublingual administering.
19. The method according to claim 11 , wherein mucosally administering comprises nasally administering.
20. The method according to claim 11 , wherein the vaccine composition is in the form of a film preparation.
21. The method according to claim 11 , wherein the vaccine composition is in the form of a liquid formulation.
22. The method according to claim 11 , wherein the vaccine composition is in the form of an orally-disintegrating tablet.